Meghan T Miller - JoVE Visualize

Showing results (11-20 of 19) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 19 results.

Cancer Research|October 7, 2004

Pancreatic insulinomas in multiple endocrine neoplasia, type I knockout mice can develop in the absence of chromosome instability or microsatellite instabilityPeter C Scacheri, Alyssa L Kennedy, Koei Chin, et al.

Plos One|February 22, 2019

Proteomic analyses reveal misregulation of LIN28 expression and delayed timing of glial differentiation in human iPS cells with MECP2 loss-of-functionJean J Kim, Jeffrey N Savas, Meghan T Miller, et al.

Child Psychiatry and Human Development|September 4, 2020

Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept ModelTom Willgoss, Daiana Cassater, Siobhan Connor, et al.

JCI Insight|August 9, 2021

Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse modelClaudia Milazzo, Edwin J Mientjes, Ilse Wallaard, et al.

Molecular Therapy. Nucleic Acids|May 20, 2022

AntimiR targeting of microRNA-134 reduces seizures in a mouse model of Angelman syndromeAoife Campbell, Gareth Morris, Albert Sanfeliu, et al.

Biological Psychiatry|March 4, 2019

Electrophysiological Phenotype in Angelman Syndrome Differs Between GenotypesJoel Frohlich, Meghan T Miller, Lynne M Bird, et al.

Elife|March 14, 2020

Agonist-mediated switching of ion selectivity in TPC2 differentially promotes lysosomal functionSusanne Gerndt, Cheng-Chang Chen, Yu-Kai Chao, et al.

Nucleic Acids Research|August 30, 2025

Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeysRavi Jagasia, Charlotte Bon, Soren V Rasmussen, et al.

Journal of Neurodevelopmental Disorders|July 26, 2023

Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)Jorrit Tjeertes, Carlos A Bacino, Terry Jo Bichell, et al.

Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 19 results.

Cancer Research|October 7, 2004

Pancreatic insulinomas in multiple endocrine neoplasia, type I knockout mice can develop in the absence of chromosome instability or microsatellite instabilityPeter C Scacheri, Alyssa L Kennedy, Koei Chin, et al.

Plos One|February 22, 2019

Proteomic analyses reveal misregulation of LIN28 expression and delayed timing of glial differentiation in human iPS cells with MECP2 loss-of-functionJean J Kim, Jeffrey N Savas, Meghan T Miller, et al.

Child Psychiatry and Human Development|September 4, 2020

Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept ModelTom Willgoss, Daiana Cassater, Siobhan Connor, et al.

JCI Insight|August 9, 2021

Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse modelClaudia Milazzo, Edwin J Mientjes, Ilse Wallaard, et al.

Molecular Therapy. Nucleic Acids|May 20, 2022

AntimiR targeting of microRNA-134 reduces seizures in a mouse model of Angelman syndromeAoife Campbell, Gareth Morris, Albert Sanfeliu, et al.

Biological Psychiatry|March 4, 2019

Electrophysiological Phenotype in Angelman Syndrome Differs Between GenotypesJoel Frohlich, Meghan T Miller, Lynne M Bird, et al.

Elife|March 14, 2020

Agonist-mediated switching of ion selectivity in TPC2 differentially promotes lysosomal functionSusanne Gerndt, Cheng-Chang Chen, Yu-Kai Chao, et al.

Nucleic Acids Research|August 30, 2025

Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeysRavi Jagasia, Charlotte Bon, Soren V Rasmussen, et al.

Journal of Neurodevelopmental Disorders|July 26, 2023

Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)Jorrit Tjeertes, Carlos A Bacino, Terry Jo Bichell, et al.

Pageof 2